G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has predictably returned. There is only one solution to this challenge: a few cups of stimulation. We are relying on cinnamon dolce and, as always, invite you to join us. Remember, no prescription is required. So no copay accumulators are involved. Meanwhile, here are some tidbits. Have a smashing day and do keep in touch …

Some of the largest Allergan (AGN) shareholders have approached potential activist investors to gauge their interest in pushing for change at the drug maker, Business Insider reports. A number of funds with top 50 positions say they have held talks with Allergan over the last several months about selling off businesses that are not central to its strategy, such as women’s health, urology, and gastroenterology. They argue the focus should be on the core aesthetics business. The funds also encouraged the activists to build a stake in Allergan to press management to change its strategy faster.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy